List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
Disrupting the interaction between the MYC oncogene and its co-factor, host cell factor (HCF)–1, was sufficient to cause Burkitt’s lymphoma cells to self-destruct in vivo.
Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.
Researchers have identified four unique subtypes of small-cell lung cancer (SCLC) following the characterisation of cell types.
A new study shows that upregulating the activity of the ACE2 signalling pathway in kidney cancer cells enhances the effects of clinically used treatments.
An antisense oligonucleotide has been developed by researchers to inhibit IRF4 as a potential strategy to treat multiple myeloma.
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
Researchers show selectively activating androgen receptors could be an effective treatment for oestrogen receptor positive breast cancers.
A study has said that restoring a particular protein's activity could be a new therapeutic strategy to treat glioblastoma.
This webinar from Bio-Techne discusses canonical and alternative oxygen sensing mechanisms implicated in cancer therapy resistance and recurrence.
Inhibiting the ACSS2 enzyme with a molecule called VY-3-135 caused a significant reduction in the growth of breast cancer tumours in vivo.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
A new study has suggested that the enzyme GFPT2 could be a useful target for non-small cell lung cancer (NSCLC).
